Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-02
1998-02-17
Fitzgerald, David L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 8, 530350, 435 691, A61K 3817, C07K 14715, C12N 1512
Patent
active
057191204
ABSTRACT:
This invention provides a novel purified TGF-.beta.-binding glycoprotein, endoglin, an isolated nucleic acid molecule that encodes an amino acid sequence corresponding to the TGF-.beta.-binding glycoprotein, soluble endoglin-derived polypeptide, and fragments thereof. A pharmaceutical composition which comprises the endoglin-derived polypeptide purified by applicants or produced by applicants' recombinant methods and a pharmaceutically acceptable carrier is further provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention.
REFERENCES:
Cheifetz and Massague, "Isoform-specific transforming growth factor-.beta. binding proteins with membrane attachments sensitive to phosphatidylinositol-specific phospholipase C." J. Biol. Chem., 268:20767-20772 (1991).
Cheifetz et al., "Endoglin is a component of the transforming growth factor-.beta. receptor system in human endothelial cells," J. Biol. Chem., 267 (27) :19027-19030 (1992).
Danielpour and Sporn, "Differential inhibition of transforming growth factor .beta.1 and .beta.2 activity by .alpha..sub.2 -mcroglobulin." J. Biol. Chem., 265 (12) :6973-6977 (1990).
Fava and McClure, "Fibronectin-associated transforming growth factor," J. Cell. Physiology, 131:184-189 (1987).
Gougos et al., "Identification of distinct epitopes of endoglin, and RGD-contaiing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts." Int'l. Immunol., 4(1):83-92 (1992).
Gougos and Letarte, "Primary structure of endoglin, and RGD-containing glycoprotein of human endothelial cells." J. Biol. chem., 265(15) :8361-8364 (1990).
Sutcliffe et al., "Antibodies that react with predetermined sites on proteins," Science, 219:660-665 (1983).
Gougos and Letarte, "Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line." J. of Immunol., 141:1925-1933 (1988).
Gougos and Letarte, "Biochemical characterization of the 44G4 antigen from the hoon pre-B leukemic cell line." J. of Immunol., 141:1934-1940 (1988).
Keski-Oja et al., "Transforming growth factors and control of neoplastic cell growth." J. Cell. Biochem., 33:95-107 (1987).
LaMarre et al., ".alpha.-macroglobulin and serum preferentially counteract the mitoinhibitory effect of transforming growth factor-.beta. in rat hepatocytes." Lab. Investigation, 65(5):545-551 (1990).
Lastres et al., "Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen." Eur. J. Immunol., 22:393-397 (1992).
Lin et al., "Expression cloning of the TGF-.beta. type II receptor, a functional transmembrane serine/threoine kinase." Cell, 68:775-785 (1992).
Lopez-Casillas et al., "Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-.beta. receptor system." Cell, 67:785-795 (1991).
MacKay et al., "Identification of disulfide-linked transforming growth factor-.beta.1-specific binding proteins in rat glomeruli." J. Biol. Chem., 265 (16):9351-9356 (1990).
MacKay and Danielpour, "Novel 150-and 180-kDa glycoproteins that bind transforming growth factor (TGF)-.beta.1 but not TGF-.beta.2 are present in several cell lines." J. Biol. Chem., 266(15):9907-9911 (1991).
Massague Joan, "The transforming growth factor-.beta. family." Ann. Rev. Cell Biol., 6:597-641 (1990).
O'Connell et al., "Endoglin: a 180-kD endothelial cell and macrophage restricted differentiation molecule." Clin. Exp. Immunol., 90:154-159 (1992).
O'Connor-McCourt and Wakefield, "Latent transforming growth factor-.beta. in serum: A specific complex with .alpha..sub.2 -maroglobulin." J. Biol. Chem., 262 (29) :14090-14099 (1987).
O'Grady et al., "Purification of a new type high molecular weight receptor (type V receptor) of transforming growth factor .beta. (TGF-.beta.) from bovine liver: Identification of the type-.beta. receptor in cultured cells." J. Biol. Chem., 266(13):8583-8589 (1991).
Quackenbush et al., "Differential localization within human kidney of five membrane proteins expressed on acute lymphoblastic leukemia cells." J. of Immunol., 136(1) :118-124 (1986).
Quackenbush and Letarte, "Identification of several cell surface proteins of non-T, non-B acute lymphoblastic leukemia by using monoclonal antibodies." J. of Immunol., 134(2):1276-1285 (1985).
Segarini and Seyedin, "The high molecular weight receptor to transforming growth factor-.beta. contains glycosaminoglycan chains." J. Biol. Chem., 263(17):8366-8370 (1988).
Sporn et al., "Some recent advances in the chemistry and biology of transforming growth factor-beta." J. Cell Biol., 105:1039-1045 (1987).
Wang et al., "Expression cloning and characterization of the TGF-.beta. type III receptor." Cell, 67:197-805 (1991).
Yamaguchi et al., "Negative regulation of transforming growth factor-.beta. by the proteoglycan decorin." Nature, 346:281-284 (1990).
Murphy-Ullrich and Hook, "Thrombospondin modulates focal adhesions in endothelial cells." J. Cell Biol., 109:1309-1319 (1989).
Paralkar et al., "Transforming growth factor .beta. type 1 binds to collagen IV of basement membrane matrix: implications for development." Dev. Biol., 143:303-308 (1991).
Andres et al., "Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth fact-.beta.." J. Cell Biol., 109:3137-3145 (1989).
Bodmer et al., "Transforming growth factor-beta bound to soluble derivatives of the beta amyloid precursor protein of alzheimer's disease." Biochem. Biophysical Res. Comm., 171(2) 890-897 (1990).
Buhring et al., "Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow." Leukemia, 5:841-847 (1991).
Cheifetz et al., "The transforming growth factor-.beta. receptor type III is a membrane proteoglycan: domain structure of the receptor." J. Biol. Chem., 263(32) :16984-16991 (1988).
Cheifetz et al., "A surface component on GH.sub.3 pituitary cells that recognized transforming growth factor-.beta., activin, and inhibin." J. Biol. Chem., 263(3):17225-17228 (1988).
Cheifetz and Massague, "Transforming growth factor-.beta. (TGF-.beta.) receptor proteoglycan: cell surface expression and ligand binding in the absence of glycosaminoglycan chains." J. Biol. Chem., 264(20) :12025-12028 (1989).
Letarte, M., et al. (1992) J. Cell Biol., Suppl. O (16, part F): p. 158, abst. No. 214.
Bernabeu Carmelo
Cheifetz Sela
Letarte Michelle
Massague Joan
Fitzgerald David L.
HSC Research & Development Limited Partnership
LandOfFree
Use of endoglin polypeptides for modifying the regulatory activi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of endoglin polypeptides for modifying the regulatory activi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of endoglin polypeptides for modifying the regulatory activi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1784018